$\require{mediawiki-texvc}$

연합인증

연합인증 가입 기관의 연구자들은 소속기관의 인증정보(ID와 암호)를 이용해 다른 대학, 연구기관, 서비스 공급자의 다양한 온라인 자원과 연구 데이터를 이용할 수 있습니다.

이는 여행자가 자국에서 발행 받은 여권으로 세계 각국을 자유롭게 여행할 수 있는 것과 같습니다.

연합인증으로 이용이 가능한 서비스는 NTIS, DataON, Edison, Kafe, Webinar 등이 있습니다.

한번의 인증절차만으로 연합인증 가입 서비스에 추가 로그인 없이 이용이 가능합니다.

다만, 연합인증을 위해서는 최초 1회만 인증 절차가 필요합니다. (회원이 아닐 경우 회원 가입이 필요합니다.)

연합인증 절차는 다음과 같습니다.

최초이용시에는
ScienceON에 로그인 → 연합인증 서비스 접속 → 로그인 (본인 확인 또는 회원가입) → 서비스 이용

그 이후에는
ScienceON 로그인 → 연합인증 서비스 접속 → 서비스 이용

연합인증을 활용하시면 KISTI가 제공하는 다양한 서비스를 편리하게 이용하실 수 있습니다.

Pharmacological Approach to the Management of Crohn’s Disease Patients with Perianal Disease

Drugs, v.78 no.1, 2018년, pp.1 - 18  

Bermejo, Fernando ,  Guerra, Iván ,  Algaba, Alicia ,  López-Sanromán, Antonio

초록이 없습니다.

참고문헌 (131)

  1. J Crohn’s Colitis. F Gomollon 11 1 3 2017 10.1093/ecco-jcc/jjw168 Gomollon F, Dignass A, Annese V, Tilg H, Van Assche G, Lindsay JO, et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: part 1: diagnosis and medical management. J Crohn’s Colitis. 2017;11(1):3-25. https://doi.org/10.1093/ecco-jcc/jjw168 . 

    crossref

  2. Inflamm Bowel Dis EK Wright 21 5 1187 2015 10.1097/MIB.0000000000000271 Wright EK, Kamm MA. Impact of drug therapy and surgery on quality of life in Crohn’s disease: a systematic review. Inflamm Bowel Dis. 2015;21(5):1187-94. https://doi.org/10.1097/MIB.0000000000000271 . 

    상세보기 crossref

  3. Dig Dis Sci M Chaparro 58 12 3400 2013 10.1007/s10620-013-2830-7 Chaparro M, Zanotti C, Burgueno P, Vera I, Bermejo F, Marin-Jimenez I, et al. Health care costs of complex perianal fistula in Crohn’s disease. Dig Dis Sci. 2013;58(12):3400-6. https://doi.org/10.1007/s10620-013-2830-7 . 

    상세보기 crossref

  4. Br J Surg. K Sahnan 2017 10.1002/bjs.10614 Sahnan K, Askari A, Adegbola SO, Tozer PJ, Phillips RKS, Hart A, et al. Natural history of anorectal sepsis. Br J Surg. 2017. https://doi.org/10.1002/bjs.10614 . 

    상세보기 crossref

  5. Inflamm Bowel Dis G Bouguen 16 8 1431 2010 10.1002/ibd.21261 Bouguen G, Siproudhis L, Bretagne JF, Bigard MA, Peyrin-Biroulet L. Nonfistulizing perianal Crohn’s disease: clinical features, epidemiology, and treatment. Inflamm Bowel Dis. 2010;16(8):1431-42. https://doi.org/10.1002/ibd.21261 . 

    상세보기 crossref

  6. Gastroenterology WJ Sandborn 125 5 1508 2003 10.1016/j.gastro.2003.08.025 Sandborn WJ, Fazio VW, Feagan BG, Hanauer SB, American Gastroenterological Association Clinical Practice C. AGA technical review on perianal Crohn’s disease. Gastroenterology. 2003;125(5):1508-30. 

    상세보기 crossref

  7. Aliment Pharmacol Ther SJ Bell 17 9 1145 2003 10.1046/j.1365-2036.2003.01561.x Bell SJ, Williams AB, Wiesel P, Wilkinson K, Cohen RC, Kamm MA. The clinical course of fistulating Crohn’s disease. Aliment Pharmacol Ther. 2003;17(9):1145-51. 

    상세보기 crossref

  8. Inflamm Bowel Dis I Molendijk 20 11 2022 2014 10.1097/MIB.0000000000000148 Molendijk I, Nuij VJ, van der Meulen-de Jong AE, van der Woude CJ. Disappointing durable remission rates in complex Crohn’s disease fistula. Inflamm Bowel Dis. 2014;20(11):2022-8. https://doi.org/10.1097/MIB.0000000000000148 . 

    상세보기 crossref

  9. 10.1111/j.1365-2036.2007.03507.x Saro C, da la Coba C, Casado MA, Morales JM, Otero B. Resource use in patients with Crohn’s disease treated with infliximab. Aliment Pharmacol Ther. 2007;26(10):1313-23. https://doi.org/10.1111/j.1365-2036.2007.03507.x . 

    상세보기 crossref

  10. Int J Colorectal Dis NP Zwintscher 30 9 1275 2015 10.1007/s00384-015-2251-5 Zwintscher NP, Shah PM, Argawal A, Chesley PM, Johnson EK, Newton CR, et al. The impact of perianal disease in young patients with inflammatory bowel disease. Int J Colorectal Dis. 2015;30(9):1275-9. https://doi.org/10.1007/s00384-015-2251-5 . 

    상세보기 crossref

  11. Tech Coloproctol S Riss 17 1 89 2013 10.1007/s10151-012-0890-x Riss S, Schwameis K, Mittlbock M, Pones M, Vogelsang H, Reinisch W, et al. Sexual function and quality of life after surgical treatment for anal fistulas in Crohn’s disease. Tech Coloproctol. 2013;17(1):89-94. https://doi.org/10.1007/s10151-012-0890-x . 

    상세보기 crossref

  12. Gut KB Gecse 63 9 1381 2014 10.1136/gutjnl-2013-306709 Gecse KB, Bemelman W, Kamm MA, Stoker J, Khanna R, Ng SC, et al. A global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn’s disease. Gut. 2014;63(9):1381-92. https://doi.org/10.1136/gutjnl-2013-306709 . 

    상세보기 crossref

  13. Inflamm Bowel Dis DA Schwartz 21 4 723 2015 10.1097/MIB.0000000000000315 Schwartz DA, Ghazi LJ, Regueiro M, Fichera A, Zoccali M, Ong EM, et al. Guidelines for the multidisciplinary management of Crohn’s perianal fistulas: summary statement. Inflamm Bowel Dis. 2015;21(4):723-30. https://doi.org/10.1097/MIB.0000000000000315 . 

    상세보기 crossref

  14. J Crohn’s Colitis. J Panes 7 7 556 2013 10.1016/j.crohns.2013.02.020 Panes J, Bouhnik Y, Reinisch W, Stoker J, Taylor SA, Baumgart DC, et al. Imaging techniques for assessment of inflammatory bowel disease: joint ECCO and ESGAR evidence-based consensus guidelines. J Crohn’s Colitis. 2013;7(7):556-85. https://doi.org/10.1016/j.crohns.2013.02.020 . 

    상세보기 crossref

  15. Colorectal Dis A Zawadzki 14 9 e608 2012 10.1111/j.1463-1318.2012.03047.x Zawadzki A, Starck M, Bohe M, Thorlacius H. A unique 3D endoanal ultrasound feature of perianal Crohn’s fistula: the ‘Crohn ultrasound fistula sign’. Colorectal Dis. 2012;14(9):e608-11. https://doi.org/10.1111/j.1463-1318.2012.03047.x . 

    상세보기 crossref

  16. Am J Gastroenterol G Maconi 102 10 2214 2007 10.1111/j.1572-0241.2007.01441.x Maconi G, Ardizzone S, Greco S, Radice E, Bezzio C, Bianchi Porro G. Transperineal ultrasound in the detection of perianal and rectovaginal fistulae in Crohn’s disease. Am J Gastroenterol. 2007;102(10):2214-9. https://doi.org/10.1111/j.1572-0241.2007.01441.x . 

    상세보기 crossref

  17. Dis Colon Rectum MR Siddiqui 55 5 576 2012 10.1097/DCR.0b013e318249d26c Siddiqui MR, Ashrafian H, Tozer P, Daulatzai N, Burling D, Hart A, et al. A diagnostic accuracy meta-analysis of endoanal ultrasound and MRI for perianal fistula assessment. Dis Colon Rectum. 2012;55(5):576-85. https://doi.org/10.1097/DCR.0b013e318249d26c . 

    상세보기 crossref

  18. Gastroenterology DA Schwartz 121 5 1064 2001 10.1053/gast.2001.28676 Schwartz DA, Wiersema MJ, Dudiak KM, Fletcher JG, Clain JE, Tremaine WJ, et al. A comparison of endoscopic ultrasound, magnetic resonance imaging, and exam under anesthesia for evaluation of Crohn’s perianal fistulas. Gastroenterology. 2001;121(5):1064-72. 

    상세보기 crossref

  19. Abdom Imaging VA Sahni 33 1 26 2008 10.1007/s00261-007-9309-y Sahni VA, Ahmad R, Burling D. Which method is best for imaging of perianal fistula? Abdom Imaging. 2008;33(1):26-30. https://doi.org/10.1007/s00261-007-9309-y . 

    상세보기 crossref

  20. J Crohn’s Colitis. P Gionchetti 11 2 135 2017 10.1093/ecco-jcc/jjw169 Gionchetti P, Dignass A, Danese S, Magro Dias FJ, Rogler G, Lakatos PL, et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: part 2: surgical management and special situations. J Crohn’s Colitis. 2017;11(2):135-49. https://doi.org/10.1093/ecco-jcc/jjw169 . 

    상세보기 crossref

  21. Dis Colon Rectum F Makowiec 40 4 443 1997 10.1007/BF02258390 Makowiec F, Jehle EC, Becker HD, Starlinger M. Perianal abscess in Crohn’s disease. Dis Colon Rectum. 1997;40(4):443-50. 

    상세보기 crossref

  22. Dis Colon Rectum YP Sangwan 39 5 529 1996 10.1007/BF02058706 Sangwan YP, Schoetz DJ Jr, Murray JJ, Roberts PL, Coller JA. Perianal Crohn’s disease. Results of local surgical treatment. Dis Colon Rectum. 1996;39(5):529-35. 

    상세보기 crossref

  23. Ann Gastroenterol. L Aguilera-Castro 30 1 33 2017 10.20524/aog.2016.0099 Aguilera-Castro L, Ferre-Aracil C, Garcia-Garcia-de-Paredes A, Rodriguez-de-Santiago E, Lopez-Sanroman A. Management of complex perianal Crohn’s disease. Ann Gastroenterol. 2017;30(1):33-44. https://doi.org/10.20524/aog.2016.0099 . 

    상세보기 crossref

  24. World J Gastroenterol M Marzo 21 5 1394 2015 10.3748/wjg.v21.i5.1394 Marzo M, Felice C, Pugliese D, Andrisani G, Mocci G, Armuzzi A, et al. Management of perianal fistulas in Crohn’s disease: an up-to-date review. World J Gastroenterol. 2015;21(5):1394-403. https://doi.org/10.3748/wjg.v21.i5.1394 . 

    상세보기 crossref

  25. Colorectal Dis EJ Groof de 18 7 667 2016 10.1111/codi.13311 de Groof EJ, Sahami S, Lucas C, Ponsioen CY, Bemelman WA, Buskens CJ. Treatment of perianal fistula in Crohn’s disease: a systematic review and meta-analysis comparing seton drainage and anti-tumour necrosis factor treatment. Colorectal Dis. 2016;18(7):667-75. https://doi.org/10.1111/codi.13311 . 

    상세보기 crossref

  26. Colorectal Dis MK Hong 13 2 171 2011 10.1111/j.1463-1318.2009.02092.x Hong MK, Craig Lynch A, Bell S, Woods RJ, Keck JO, Johnston MJ, et al. Faecal diversion in the management of perianal Crohn’s disease. Colorectal Dis. 2011;13(2):171-6. https://doi.org/10.1111/j.1463-1318.2009.02092.x . 

    상세보기 crossref

  27. Br J Surg. CM Edwards 87 8 1063 2000 10.1046/j.1365-2168.2000.01467.x Edwards CM, George BD, Jewell DP, Warren BF, Mortensen NJ, Kettlewell MG. Role of a defunctioning stoma in the management of large bowel Crohn’s disease. Br J Surg. 2000;87(8):1063-6. https://doi.org/10.1046/j.1365-2168.2000.01467.x . 

    상세보기 crossref

  28. Aliment Pharmacol Ther S Singh 42 7 783 2015 10.1111/apt.13356 Singh S, Ding NS, Mathis KL, Dulai PS, Farrell AM, Pemberton JH, et al. Systematic review with meta-analysis: faecal diversion for management of perianal Crohn’s disease. Aliment Pharmacol Ther. 2015;42(7):783-92. https://doi.org/10.1111/apt.13356 . 

    상세보기 crossref

  29. Dtsch Med Wochenschr MU Schneider 110 45 1724 1985 10.1055/s-2008-1069077 Schneider MU, Laudage G, Guggenmoos-Holzmann I, Riemann JF. Metronidazole in the treatment of Crohn disease. Results of a controlled randomized prospective study. Dtsch Med Wochenschr. 1985;110(45):1724-30. https://doi.org/10.1055/s-2008-1069077 . 

    상세보기 crossref

  30. Gastroenterology LH Bernstein 79 3 599 1980 10.1016/0016-5085(80)90402-3 Bernstein LH, Frank MS, Brandt LJ, Boley SJ. Healing of perineal Crohn’s disease with metronidazole. Gastroenterology. 1980;79(3):599. 

    상세보기 crossref

  31. Am J Gastroenterol. J Jakobovits 79 7 533 1984 Jakobovits J, Schuster MM. Metronidazole therapy for Crohn’s disease and associated fistulae. Am J Gastroenterol. 1984;79(7):533-40. 

    상세보기

  32. Gastroenterology LJ Brandt 83 2 383 1982 10.1016/S0016-5085(82)80332-6 Brandt LJ, Bernstein LH, Boley SJ, Frank MS. Metronidazole therapy for perineal Crohn’s disease: a follow-up study. Gastroenterology. 1982;83(2):383-7. 

    상세보기 crossref

  33. Br J Surg. Y Maeda 97 9 1340 2010 10.1002/bjs.7121 Maeda Y, Ng SC, Durdey P, Burt C, Torkington J, Rao PK, et al. Randomized clinical trial of metronidazole ointment versus placebo in perianal Crohn’s disease. Br J Surg. 2010;97(9):1340-7. https://doi.org/10.1002/bjs.7121 . 

    상세보기 crossref

  34. Dis Colon Rectum EE Stringer 48 5 970 2005 10.1007/s10350-004-0873-8 Stringer EE, Nicholson TJ, Armstrong D. Efficacy of topical metronidazole (10 percent) in the treatment of anorectal Crohn’s disease. Dis Colon Rectum. 2005;48(5):970-4. https://doi.org/10.1007/s10350-004-0873-8 . 

    상세보기 crossref

  35. Gastroenterology UM Turunen 115 5 1072 1998 10.1016/S0016-5085(98)70076-9 Turunen UM, Farkkila MA, Hakala K, Seppala K, Sivonen A, Ogren M, et al. Long-term treatment of ulcerative colitis with ciprofloxacin: a prospective, double-blind, placebo-controlled study. Gastroenterology. 1998;115(5):1072-8. 

    상세보기 crossref

  36. Wolf J. Ciprofloxacin may be useful in Crohn’s disease. Gastroenterology. 1990;98:A212 (Abstract). 

  37. Crohns Dis. MJMR Solomon 7 571 1993 Solomon MJMR, Oconnor BI. Combination ciprofloxacin and metronidazole in severe perianal. Crohns Dis. 1993;7:571-3. 

  38. Inflamm Bowel Dis KT Thia 15 1 17 2009 10.1002/ibd.20608 Thia KT, Mahadevan U, Feagan BG, Wong C, Cockeram A, Bitton A, et al. Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn’s disease: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis. 2009;15(1):17-24. https://doi.org/10.1002/ibd.20608 . 

    상세보기 crossref

  39. Am J Gastroenterol. KJ Khan 106 4 661 2011 10.1038/ajg.2011.72 Khan KJ, Ullman TA, Ford AC, Abreu MT, Abadir A, Marshall JK, et al. Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol. 2011;106(4):661-73. https://doi.org/10.1038/ajg.2011.72 . 

    상세보기 crossref

  40. Aliment Pharmacol Ther C Dejaco 18 11-12 1113 2003 10.1046/j.1365-2036.2003.01793.x Dejaco C, Harrer M, Waldhoer T, Miehsler W, Vogelsang H, Reinisch W. Antibiotics and azathioprine for the treatment of perianal fistulas in Crohn’s disease. Aliment Pharmacol Ther. 2003;18(11-12):1113-20. 

    상세보기 crossref

  41. Aliment Pharmacol Ther RL West 20 11-12 1329 2004 10.1111/j.1365-2036.2004.02247.x West RL, van der Woude CJ, Hansen BE, Felt-Bersma RJ, van Tilburg AJ, Drapers JA, et al. Clinical and endosonographic effect of ciprofloxacin on the treatment of perianal fistulae in Crohn’s disease with infliximab: a double-blind placebo-controlled study. Aliment Pharmacol Ther. 2004;20(11-12):1329-36. https://doi.org/10.1111/j.1365-2036.2004.02247.x . 

    상세보기 crossref

  42. Gut P Dewint 63 2 292 2014 10.1136/gutjnl-2013-304488 Dewint P, Hansen BE, Verhey E, Oldenburg B, Hommes DW, Pierik M, et al. Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn’s disease: a randomised, double-blind, placebo controlled trial (ADAFI). Gut. 2014;63(2):292-9. https://doi.org/10.1136/gutjnl-2013-304488 . 

    상세보기 crossref

  43. Ann Intern Med. DC Pearson 123 2 132 1995 10.7326/0003-4819-123-2-199507150-00009 Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med. 1995;123(2):132-42. 

    상세보기 crossref

  44. 10.1053/j.gastro.2013.04.048 Cosnes J, Bourrier A, Laharie D, Nahon S, Bouhnik Y, Carbonnel F, et al. Early administration of azathioprine vs conventional management of Crohn’s Disease: a randomized controlled trial. Gastroenterology. 2013;145(4):758-65 e2. https://doi.org/10.1053/j.gastro.2013.04.048 (quiz e14-5). 

    상세보기 crossref

  45. Inflamm Bowel Dis VC Kariyawasam 20 8 1382 2014 10.1097/MIB.0000000000000119 Kariyawasam VC, Selinger CP, Katelaris PH, Jones DB, McDonald C, Barr G, et al. Early use of thiopurines or methotrexate reduces major abdominal and perianal surgery in Crohn’s disease. Inflamm Bowel Dis. 2014;20(8):1382-90. https://doi.org/10.1097/MIB.0000000000000119 . 

    상세보기 crossref

  46. Inflamm Bowel Dis AL Hart 13 3 245 2007 10.1002/ibd.20073 Hart AL, Plamondon S, Kamm MA. Topical tacrolimus in the treatment of perianal Crohn’s disease: exploratory randomized controlled trial. Inflamm Bowel Dis. 2007;13(3):245-53. https://doi.org/10.1002/ibd.20073 . 

    상세보기 crossref

  47. Turk J Gastroenterol. H Cat 14 2 121 2003 Cat H, Sophani I, Lemann M, Modiglani R, Solue JC. Cyclosporin treatment of anal and perianal lesions associated with Crohn’s disease. Turk J Gastroenterol. 2003;14(2):121-7. 

    상세보기

  48. Am J Gastroenterol. SB Hanauer 88 5 646 1993 Hanauer SB, Smith MB. Rapid closure of Crohn’s disease fistulas with continuous intravenous cyclosporin A. Am J Gastroenterol. 1993;88(5):646-9. 

    상세보기

  49. Dig Dis Sci DH Present 39 2 374 1994 10.1007/BF02090211 Present DH, Lichtiger S. Efficacy of cyclosporine in treatment of fistula of Crohn’s disease. Dig Dis Sci. 1994;39(2):374-80. 

    상세보기 crossref

  50. Aliment Pharmacol Ther C Yang 41 11 1079 2015 10.1111/apt.13181 Yang C, Singh P, Singh H, Le ML, El-Matary W. Systematic review: thalidomide and thalidomide analogues for treatment of inflammatory bowel disease. Aliment Pharmacol Ther. 2015;41(11):1079-93. https://doi.org/10.1111/apt.13181 . 

    상세보기 crossref

  51. N Engl J Med DH Present 340 18 1398 1999 10.1056/NEJM199905063401804 Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med. 1999;340(18):1398-405. https://doi.org/10.1056/NEJM199905063401804 . 

    상세보기 crossref

  52. N Engl J Med BE Sands 350 9 876 2004 10.1056/NEJMoa030815 Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med. 2004;350(9):876-85. https://doi.org/10.1056/NEJMoa030815 . 

    상세보기 crossref

  53. Gastroenterology GR Lichtenstein 128 4 862 2005 10.1053/j.gastro.2005.01.048 Lichtenstein GR, Yan S, Bala M, Blank M, Sands BE. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn’s disease. Gastroenterology. 2005;128(4):862-9. 

    상세보기 crossref

  54. Am J Gastroenterol. RJ Farrell 95 12 3490 2000 10.1111/j.1572-0241.2000.03366.x Farrell RJ, Shah SA, Lodhavia PJ, Alsahli M, Falchuk KR, Michetti P, et al. Clinical experience with infliximab therapy in 100 patients with Crohn’s disease. Am J Gastroenterol. 2000;95(12):3490-7. https://doi.org/10.1111/j.1572-0241.2000.03366.x . 

    상세보기 crossref

  55. Am J Gastroenterol. E Ricart 96 3 722 2001 10.1111/j.1572-0241.2001.03612.x Ricart E, Panaccione R, Loftus EV, Tremaine WJ, Sandborn WJ. Infliximab for Crohn’s disease in clinical practice at the Mayo Clinic: the first 100 patients. Am J Gastroenterol. 2001;96(3):722-9. https://doi.org/10.1111/j.1572-0241.2001.03612.x . 

    상세보기 crossref

  56. 10.1016/j.cgh.2012.12.042 Bouguen G, Siproudhis L, Gizard E, Wallenhorst T, Billioud V, Bretagne JF, et al. Long-term outcome of perianal fistulizing Crohn’s disease treated with infliximab. Clin Gastroenterol Hepatol. 2013;11(8):975-81 e1-4. https://doi.org/10.1016/j.cgh.2012.12.042 . 

    상세보기 crossref

  57. Gastroenterology JF Colombel 132 1 52 2007 10.1053/j.gastro.2006.11.041 Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology. 2007;132(1):52-65. https://doi.org/10.1053/j.gastro.2006.11.041 . 

    상세보기 crossref

  58. Gut JF Colombel 58 7 940 2009 10.1136/gut.2008.159251 Colombel JF, Schwartz DA, Sandborn WJ, Kamm MA, D’Haens G, Rutgeerts P, et al. Adalimumab for the treatment of fistulas in patients with Crohn’s disease. Gut. 2009;58(7):940-8. https://doi.org/10.1136/gut.2008.159251 . 

    상세보기 crossref

  59. Aliment Pharmacol Ther J Hinojosa 25 4 409 2007 10.1111/j.1365-2036.2006.03232.x Hinojosa J, Gomollon F, Garcia S, Bastida G, Cabriada JL, Saro C, et al. Efficacy and safety of short-term adalimumab treatment in patients with active Crohn’s disease who lost response or showed intolerance to infliximab: a prospective, open-label, multicentre trial. Aliment Pharmacol Ther. 2007;25(4):409-18. https://doi.org/10.1111/j.1365-2036.2006.03232.x . 

    상세보기 crossref

  60. Can J Gastroenterol. R Panaccione 25 8 419 2011 10.1155/2011/724813 Panaccione R, Loftus EV Jr, Binion D, McHugh K, Alam S, Chen N, et al. Efficacy and safety of adalimumab in Canadian patients with moderate to severe Crohn’s disease: results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn’s DiseaSe (ACCESS) trial. Can J Gastroenterol. 2011;25(8):419-25. 

    상세보기 crossref

  61. Aliment Pharmacol Ther S Lichtiger 32 10 1228 2010 10.1111/j.1365-2036.2010.04466.x Lichtiger S, Binion DG, Wolf DC, Present DH, Bensimon AG, Wu E, et al. The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn’s disease who failed prior infliximab therapy. Aliment Pharmacol Ther. 2010;32(10):1228-39. https://doi.org/10.1111/j.1365-2036.2010.04466.x . 

    상세보기 crossref

  62. Inflamm Bowel Dis M Regueiro 9 2 98 2003 10.1097/00054725-200303000-00003 Regueiro M, Mardini H. Treatment of perianal fistulizing Crohn’s disease with infliximab alone or as an adjunct to exam under anesthesia with seton placement. Inflamm Bowel Dis. 2003;9(2):98-103. 

    상세보기 crossref

  63. Dis Colon Rectum WB Gaertner 50 11 1754 2007 10.1007/s10350-007-9077-3 Gaertner WB, Decanini A, Mellgren A, Lowry AC, Goldberg SM, Madoff RD, et al. Does infliximab infusion impact results of operative treatment for Crohn’s perianal fistulas? Dis Colon Rectum. 2007;50(11):1754-60. https://doi.org/10.1007/s10350-007-9077-3 . 

    상세보기 crossref

  64. Aliment Pharmacol Ther NA Yassin 40 7 741 2014 10.1111/apt.12906 Yassin NA, Askari A, Warusavitarne J, Faiz OD, Athanasiou T, Phillips RK, et al. Systematic review: the combined surgical and medical treatment of fistulising perianal Crohn’s disease. Aliment Pharmacol Ther. 2014;40(7):741-9. https://doi.org/10.1111/apt.12906 . 

    상세보기 crossref

  65. N Engl J Med S Schreiber 357 3 239 2007 10.1056/NEJMoa062897 Schreiber S, Khaliq-Kareemi M, Lawrance IC, Thomsen OO, Hanauer SB, McColm J, et al. Maintenance therapy with certolizumab pegol for Crohn’s disease. N Engl J Med. 2007;357(3):239-50. https://doi.org/10.1056/NEJMoa062897 . 

    상세보기 crossref

  66. N Engl J Med WJ Sandborn 357 3 228 2007 10.1056/NEJMoa067594 Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D, et al. Certolizumab pegol for the treatment of Crohn’s disease. N Engl J Med. 2007;357(3):228-38. https://doi.org/10.1056/NEJMoa067594 . 

    상세보기 crossref

  67. Aliment Pharmacol Ther S Schreiber 33 2 185 2011 10.1111/j.1365-2036.2010.04509.x Schreiber S, Lawrance IC, Thomsen OO, Hanauer SB, Bloomfield R, Sandborn WJ. Randomised clinical trial: certolizumab pegol for fistulas in Crohn’s disease - subgroup results from a placebo-controlled study. Aliment Pharmacol Ther. 2011;33(2):185-93. https://doi.org/10.1111/j.1365-2036.2010.04509.x . 

    상세보기 crossref

  68. Clin Exp Gastroenterol I Guerra 7 359 2014 10.2147/CEG.S45297 Guerra I, Bermejo F. Management of inflammatory bowel disease in poor responders to infliximab. Clin Exp Gastroenterol. 2014;7:359-67. https://doi.org/10.2147/CEG.S45297 . 

    상세보기 crossref

  69. Aliment Pharmacol Ther AJ Yarur 45 7 933 2017 10.1111/apt.13970 Yarur AJ, Kanagala V, Stein DJ, Czul F, Quintero MA, Agrawal D, et al. Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn’s disease. Aliment Pharmacol Ther. 2017;45(7):933-40. https://doi.org/10.1111/apt.13970 . 

    상세보기 crossref

  70. J Crohn’s Colitis. Y Davidov 11 5 549 2017 10.1093/ecco-jcc/jjw182 Davidov Y, Ungar B, Bar-Yoseph H, Carter D, Haj-Natour O, Yavzori M, et al. Association of induction infliximab levels with clinical response in perianal Crohn’s disease. J Crohn’s Colitis. 2017;11(5):549-55. https://doi.org/10.1093/ecco-jcc/jjw182 . 

    crossref

  71. 10.1016/j.cgh.2014.12.026 Yarur AJ, Kubiliun MJ, Czul F, Sussman DA, Quintero MA, Jain A, et al. Concentrations of 6-thioguanine nucleotide correlate with trough levels of infliximab in patients with inflammatory bowel disease on combination therapy. Clin Gastroenterol Hepatol. 2015;13(6):1118-24 e3. https://doi.org/10.1016/j.cgh.2014.12.026 . 

    상세보기 crossref

  72. Dis Colon Rectum G Poggioli 48 4 768 2005 10.1007/s10350-004-0832-4 Poggioli G, Laureti S, Pierangeli F, Rizzello F, Ugolini F, Gionchetti P, et al. Local injection of Infliximab for the treatment of perianal Crohn’s disease. Dis Colon Rectum. 2005;48(4):768-74. https://doi.org/10.1007/s10350-004-0832-4 . 

    상세보기 crossref

  73. Scand J Gastroenterol CR Asteria 41 9 1064 2006 10.1080/00365520600609941 Asteria CR, Ficari F, Bagnoli S, Milla M, Tonelli F. Treatment of perianal fistulas in Crohn’s disease by local injection of antibody to TNF-alpha accounts for a favourable clinical response in selected cases: a pilot study. Scand J Gastroenterol. 2006;41(9):1064-72. https://doi.org/10.1080/00365520600609941 . 

    상세보기 crossref

  74. Inflamm Bowel Dis G Poggioli 16 10 1631 2010 10.1002/ibd.21210 Poggioli G, Laureti S, Pierangeli F, Bazzi P, Coscia M, Gentilini L, et al. Local injection of adalimumab for perianal Crohn’s disease: better than infliximab? Inflamm Bowel Dis. 2010;16(10):1631. https://doi.org/10.1002/ibd.21210 . 

    상세보기 crossref

  75. Dis Colon Rectum F Tonelli 55 8 870 2012 10.1097/DCR.0b013e31825af532 Tonelli F, Giudici F, Asteria CR. Effectiveness and safety of local adalimumab injection in patients with fistulizing perianal Crohn’s disease: a pilot study. Dis Colon Rectum. 2012;55(8):870-5. https://doi.org/10.1097/DCR.0b013e31825af532 . 

    상세보기 crossref

  76. Int J Colorectal Dis SO Adegbola 2017 10.1007/s00384-017-2899-0 Adegbola SO, Sahnan K, Tozer PJ, Phillips RK, Faiz OD, Warusavitarne J, et al. Review of local injection of anti-TNF for perianal fistulising Crohn’s disease. Int J Colorectal Dis. 2017. https://doi.org/10.1007/s00384-017-2899-0 . 

    상세보기 crossref

  77. Inflamm Bowel Dis S Ardizzone 10 2 91 2004 10.1097/00054725-200403000-00005 Ardizzone S, Maconi G, Colombo E, Manzionna G, Bollani S, Bianchi Porro G. Perianal fistulae following infliximab treatment: clinical and endosonographic outcome. Inflamm Bowel Dis. 2004;10(2):91-6. 

    상세보기 crossref

  78. Am J Gastroenterol. G Assche Van 98 2 332 2003 10.1111/j.1572-0241.2003.07241.x Van Assche G, Vanbeckevoort D, Bielen D, Coremans G, Aerden I, Noman M, et al. Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn’s disease. Am J Gastroenterol. 2003;98(2):332-9. https://doi.org/10.1111/j.1572-0241.2003.07241.x . 

    상세보기 crossref

  79. Drugs. RM Poole 74 11 1293 2014 10.1007/s40265-014-0253-1 Poole RM. Vedolizumab: first global approval. Drugs. 2014;74(11):1293-303. https://doi.org/10.1007/s40265-014-0253-1 . 

    상세보기 crossref

  80. N Engl J Med WJ Sandborn 369 8 711 2013 10.1056/NEJMoa1215739 Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013;369(8):711-21. https://doi.org/10.1056/NEJMoa1215739 . 

    상세보기 crossref

  81. 10.1016/S0016-5085(15)30901-X Feagan B, Schwartz D, Danese S, Rubin DT, Abhyankar B, Smyth M, Xu J, Lasch K. Vedolizumab for the treatment of fistulizing Crohn’s disease: an exploratory analysis of data from GEMINI 2. J Crohn’s Collitis. 2015;9(Suppl_1):S333. 

    상세보기 crossref

  82. 10.1016/S0016-5085(15)32937-1 Christensen B, Goeppinger S, Colman R, Siddiqui D, Yarur A, Bochenek AA, Wichmann A, Hirsch A, Kinnucan J, Sakuraba A, Cohen R, Rubin DT. Post-marketing experience of vedolizumab for IBD: the university of Chicago experience. J Crohn’s Colitis. 2015;9(Suppl_1):S388. 

    상세보기 crossref

  83. Am J Gastroenterol. PS Dulai 111 8 1147 2016 10.1038/ajg.2016.236 Dulai PS, Singh S, Jiang X, Peerani F, Narula N, Chaudrey K, et al. The real-world effectiveness and safety of vedolizumab for moderate-severe Crohn’s disease: results from the US VICTORY consortium. Am J Gastroenterol. 2016;111(8):1147-55. https://doi.org/10.1038/ajg.2016.236 . 

    상세보기 crossref

  84. 10.1093/ecco-jcc/jjx002.062 Tadbiri S, Grimaud J, Peyrin-Biroulet L, Filippi J, Pariente B, Roblin X, Buisson A, Stefanescu C, Trang-Poisson C, Altwegg R, Marteau P, Vaysse T, Bourrier A, Nancey S, Laharie D, Allez M, Bouhnik Y, Amiot A. Efficacy of vedolizumab on extraintestinal manifestation in patients with inflammatory bowel disease: a posthoc analysis of the OBSERV-IBD cohort from the GETAID. J Crohn’s Collitis. 2017;11(Suppl_1):S42. 

    crossref

  85. Vedolizumab IV 300 mg in the Treatment of Fistulizing Crohn’s Disease (ENTERPRISE). https://clinicaltrials.gov/ct2/show/NCT0280%630966 . 

  86. Drugs. YN Lamb 77 10 1105 2017 10.1007/s40265-017-0765-6 Lamb YN, Duggan ST. Ustekinumab: a review in moderate to severe Crohn’s disease. Drugs. 2017;77(10):1105-14. https://doi.org/10.1007/s40265-017-0765-6 . 

    상세보기 crossref

  87. J Crohn’s Colitis. U Kopylov 8 11 1516 2014 10.1016/j.crohns.2014.06.005 Kopylov U, Afif W, Cohen A, Bitton A, Wild G, Bessissow T, et al. Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn’s disease-the McGill experience. J Crohn’s Colitis. 2014;8(11):1516-22. https://doi.org/10.1016/j.crohns.2014.06.005 . 

    상세보기 crossref

  88. 10.1016/j.cgh.2015.09.018 Wils P, Bouhnik Y, Michetti P, Flourie B, Brixi H, Bourrier A, et al. Subcutaneous ustekinumab provides clinical benefit for two-thirds of patients with Crohn’s disease refractory to anti-tumor necrosis factor agents. Clin Gastroenterol Hepatol. 2016;14(2):242-50 e1-2. https://doi.org/10.1016/j.cgh.2015.09.018 . 

    상세보기 crossref

  89. Inflamm Bowel Dis S Khorrami 22 7 1662 2016 10.1097/MIB.0000000000000842 Khorrami S, Ginard D, Marin-Jimenez I, Chaparro M, Sierra M, Aguas M, et al. Ustekinumab for the treatment of refractory Crohn’s disease: the Spanish experience in a large multicentre open-label cohort. Inflamm Bowel Dis. 2016;22(7):1662-9. https://doi.org/10.1097/MIB.0000000000000842 . 

    상세보기 crossref

  90. Aliment Pharmacol Ther C Ma 45 9 1232 2017 10.1111/apt.14016 Ma C, Fedorak RN, Kaplan GG, Dieleman LA, Devlin SM, Stern N, et al. Clinical, endoscopic and radiographic outcomes with ustekinumab in medically-refractory Crohn’s disease: real world experience from a multicentre cohort. Aliment Pharmacol Ther. 2017;45(9):1232-43. https://doi.org/10.1111/apt.14016 . 

    상세보기 crossref

  91. Gastroenterology B Sands 152 5 S185 2017 10.1016/S0016-5085(17)30930-7 Sands B, Gasink C, Jacobstein D, Gao L, Johanns J, Colombel JF, de Villiers WJ, Sandborn WJ. Fistula healing in pivotal studies of ustekinumab in Crohn’s disease. Gastroenterology. 2017;152(5):S185. 

    상세보기 crossref

  92. N Engl J Med BG Feagan 375 20 1946 2016 10.1056/NEJMoa1602773 Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, et al. Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2016;375(20):1946-60. https://doi.org/10.1056/NEJMoa1602773 . 

    상세보기 crossref

  93. N Engl J Med WJ Sandborn 367 16 1519 2012 10.1056/NEJMoa1203572 Sandborn WJ, Gasink C, Gao LL, Blank MA, Johanns J, Guzzo C, et al. Ustekinumab induction and maintenance therapy in refractory Crohn’s disease. N Engl J Med. 2012;367(16):1519-28. https://doi.org/10.1056/NEJMoa1203572 . 

    상세보기 crossref

  94. Ann Gastroenterol. CB Geltzeiler 27 4 320 2014 Geltzeiler CB, Wieghard N, Tsikitis VL. Recent developments in the surgical management of perianal fistula for Crohn’s disease. Ann Gastroenterol. 2014;27(4):320-30. 

    상세보기

  95. Expert Opin Biol Ther. I Garcia-Gomez 10 10 1453 2010 10.1517/14712598.2010.519333 Garcia-Gomez I, Elvira G, Zapata AG, Lamana ML, Ramirez M, Castro JG, et al. Mesenchymal stem cells: biological properties and clinical applications. Expert Opin Biol Ther. 2010;10(10):1453-68. https://doi.org/10.1517/14712598.2010.519333 . 

    상세보기 crossref

  96. Int J Hematol N Kim 103 2 129 2016 10.1007/s12185-015-1918-6 Kim N, Cho SG. Overcoming immunoregulatory plasticity of mesenchymal stem cells for accelerated clinical applications. Int J Hematol. 2016;103(2):129-37. https://doi.org/10.1007/s12185-015-1918-6 . 

    상세보기 crossref

  97. Gut R Ciccocioppo 60 6 788 2011 10.1136/gut.2010.214841 Ciccocioppo R, Bernardo ME, Sgarella A, Maccario R, Avanzini MA, Ubezio C, et al. Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn’s disease. Gut. 2011;60(6):788-98. https://doi.org/10.1136/gut.2010.214841 . 

    상세보기 crossref

  98. Stem Cell Res Ther. R Ciccocioppo 6 137 2015 10.1186/s13287-015-0122-1 Ciccocioppo R, Cangemi GC, Kruzliak P, Gallia A, Betti E, Badulli C, et al. Ex vivo immunosuppressive effects of mesenchymal stem cells on Crohn’s disease mucosal T cells are largely dependent on indoleamine 2,3-dioxygenase activity and cell-cell contact. Stem Cell Res Ther. 2015;6:137. https://doi.org/10.1186/s13287-015-0122-1 . 

    상세보기 crossref

  99. Blood SM Devine 101 8 2999 2003 10.1182/blood-2002-06-1830 Devine SM, Cobbs C, Jennings M, Bartholomew A, Hoffman R. Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates. Blood. 2003;101(8):2999-3001. https://doi.org/10.1182/blood-2002-06-1830 . 

    상세보기 crossref

  100. Nat Immunol Y Wang 15 11 1009 2014 10.1038/ni.3002 Wang Y, Chen X, Cao W, Shi Y. Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications. Nat Immunol. 2014;15(11):1009-16. https://doi.org/10.1038/ni.3002 . 

    상세보기 crossref

  101. World J Gastroenterol D Garcia-Olmo 21 11 3330 2015 10.3748/wjg.v21.i11.3330 Garcia-Olmo D, Guadalajara H, Rubio-Perez I, Herreros MD, de-la-Quintana P, Garcia-Arranz M. Recurrent anal fistulae: limited surgery supported by stem cells. World J Gastroenterol. 2015;21(11):3330-6. https://doi.org/10.3748/wjg.v21.i11.3330 . 

    상세보기 crossref

  102. Stem Cells Transl Med. SM Melief 2 6 455 2013 10.5966/sctm.2012-0184 Melief SM, Zwaginga JJ, Fibbe WE, Roelofs H. Adipose tissue-derived multipotent stromal cells have a higher immunomodulatory capacity than their bone marrow-derived counterparts. Stem Cells Transl Med. 2013;2(6):455-63. https://doi.org/10.5966/sctm.2012-0184 . 

    상세보기 crossref

  103. Dis Colon Rectum D Garcia-Olmo 52 1 79 2009 10.1007/DCR.0b013e3181973487 Garcia-Olmo D, Herreros D, Pascual I, Pascual JA, Del-Valle E, Zorrilla J, et al. Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Dis Colon Rectum. 2009;52(1):79-86. https://doi.org/10.1007/DCR.0b013e3181973487 . 

    상세보기 crossref

  104. Lancet J Panes 388 10051 1281 2016 10.1016/S0140-6736(16)31203-X Panes J, Garcia-Olmo D, Van Assche G, Colombel JF, Reinisch W, Baumgart DC, et al. Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn’s disease: a phase 3 randomised, double-blind controlled trial. Lancet. 2016;388(10051):1281-90. https://doi.org/10.1016/S0140-6736(16)31203-X . 

    상세보기 crossref

  105. J Crohn’s Colitis. AL Lightner 2017 10.1093/ecco-jcc/jjx046 Lightner AL, Faubion WA. Mesenchymal stem cell injections for the treatment of perianal Crohn’s disease: what we’ve accomplished and what we still need to do. J Crohn’s Colitis. 2017. https://doi.org/10.1093/ecco-jcc/jjx046 . 

    상세보기 crossref

  106. Gastroenterology D Garcia-Olmo 149 4 853 2015 10.1053/j.gastro.2015.08.038 Garcia-Olmo D, Schwartz DA. Cumulative evidence that mesenchymal stem cells promote healing of perianal fistulas of patients with Crohn’s disease-going from bench to bedside. Gastroenterology. 2015;149(4):853-7. https://doi.org/10.1053/j.gastro.2015.08.038 . 

    상세보기 crossref

  107. Stem Cells. WY Lee 31 11 2575 2013 10.1002/stem.1357 Lee WY, Park KJ, Cho YB, Yoon SN, Song KH, Kim DS, et al. Autologous adipose tissue-derived stem cells treatment demonstrated favorable and sustainable therapeutic effect for Crohn’s fistula. Stem Cells. 2013;31(11):2575-81. https://doi.org/10.1002/stem.1357 . 

    상세보기 crossref

  108. 10.1053/j.gastro.2015.06.014 Molendijk I, Bonsing BA, Roelofs H, Peeters KC, Wasser MN, Dijkstra G, et al. Allogeneic bone marrow-derived mesenchymal stromal cells promote healing of refractory perianal fistulas in patients with Crohn’s disease. Gastroenterology. 2015;149(4):918-27 e6. https://doi.org/10.1053/j.gastro.2015.06.014 . 

    상세보기 crossref

  109. Int J Colorectal Dis D Garcia-Olmo 18 5 451 2003 10.1007/s00384-003-0490-3 Garcia-Olmo D, Garcia-Arranz M, Garcia LG, Cuellar ES, Blanco IF, Prianes LA, et al. Autologous stem cell transplantation for treatment of rectovaginal fistula in perianal Crohn’s disease: a new cell-based therapy. Int J Colorectal Dis. 2003;18(5):451-4. https://doi.org/10.1007/s00384-003-0490-3 . 

    상세보기 crossref

  110. Dis Colon Rectum D Garcia-Olmo 48 7 1416 2005 10.1007/s10350-005-0052-6 Garcia-Olmo D, Garcia-Arranz M, Herreros D, Pascual I, Peiro C, Rodriguez-Montes JA. A phase I clinical trial of the treatment of Crohn’s fistula by adipose mesenchymal stem cell transplantation. Dis Colon Rectum. 2005;48(7):1416-23. https://doi.org/10.1007/s10350-005-0052-6 . 

    상세보기 crossref

  111. Int J Colorectal Dis H Guadalajara 27 5 595 2012 10.1007/s00384-011-1350-1 Guadalajara H, Herreros D, De-La-Quintana P, Trebol J, Garcia-Arranz M, Garcia-Olmo D. Long-term follow-up of patients undergoing adipose-derived adult stem cell administration to treat complex perianal fistulas. Int J Colorectal Dis. 2012;27(5):595-600. https://doi.org/10.1007/s00384-011-1350-1 . 

    상세보기 crossref

  112. Cell Transplant YB Cho 22 2 279 2013 10.3727/096368912X656045 Cho YB, Lee WY, Park KJ, Kim M, Yoo HW, Yu CS. Autologous adipose tissue-derived stem cells for the treatment of Crohn’s fistula: a phase I clinical study. Cell Transplant. 2013;22(2):279-85. https://doi.org/10.3727/096368912X656045 . 

    상세보기 crossref

  113. Stem Cells Transl Med. YB Cho 4 5 532 2015 10.5966/sctm.2014-0199 Cho YB, Park KJ, Yoon SN, Song KH, Kim DS, Jung SH, et al. Long-term results of adipose-derived stem cell therapy for the treatment of Crohn’s fistula. Stem Cells Transl Med. 2015;4(5):532-7. https://doi.org/10.5966/sctm.2014-0199 . 

    상세보기 crossref

  114. 10.1053/j.gastro.2017.04.001 Dietz AB, Dozois EJ, Fletcher JG, Butler GW, Radel D, Lightner AL, et al. Autologous mesenchymal stem cells, applied in a bioabsorbable matrix, for treatment of perianal fistulas in patients with Crohn’s disease. Gastroenterology. 2017;153(1):59-62 e2. https://doi.org/10.1053/j.gastro.2017.04.001 . 

    상세보기 crossref

  115. Tech Coloproctol S Choi 21 5 345 2017 10.1007/s10151-017-1630-z Choi S, Ryoo SB, Park KJ, Kim DS, Song KH, Kim KH, et al. Autologous adipose tissue-derived stem cells for the treatment of complex perianal fistulas not associated with Crohn’s disease: a phase II clinical trial for safety and efficacy. Tech Coloproctol. 2017;21(5):345-53. https://doi.org/10.1007/s10151-017-1630-z . 

    상세보기 crossref

  116. Mayo Clin Proc R Ciccocioppo 90 6 747 2015 10.1016/j.mayocp.2015.03.023 Ciccocioppo R, Gallia A, Sgarella A, Kruzliak P, Gobbi PG, Corazza GR. Long-term follow-up of crohn disease fistulas after local injections of bone marrow-derived mesenchymal stem cells. Mayo Clin Proc. 2015;90(6):747-55. https://doi.org/10.1016/j.mayocp.2015.03.023 . 

    상세보기 crossref

  117. Int J Colorectal Dis F Portilla de la 28 3 313 2013 10.1007/s00384-012-1581-9 de la Portilla F, Alba F, Garcia-Olmo D, Herrerias JM, Gonzalez FX, Galindo A. Expanded allogeneic adipose-derived stem cells (eASCs) for the treatment of complex perianal fistula in Crohn’s disease: results from a multicenter phase I/IIa clinical trial. Int J Colorectal Dis. 2013;28(3):313-23. https://doi.org/10.1007/s00384-012-1581-9 . 

    상세보기 crossref

  118. Colorectal Dis KJ Park 18 5 468 2016 10.1111/codi.13223 Park KJ, Ryoo SB, Kim JS, Kim TI, Baik SH, Kim HJ, et al. Allogeneic adipose-derived stem cells for the treatment of perianal fistula in Crohn’s disease: a pilot clinical trial. Colorectal Dis. 2016;18(5):468-76. https://doi.org/10.1111/codi.13223 . 

    상세보기 crossref

  119. Expert Opin Biol Ther. PJ Mannon 11 9 1249 2011 10.1517/14712598.2011.602967 Mannon PJ. Remestemcel-L: human mesenchymal stem cells as an emerging therapy for Crohn’s disease. Expert Opin Biol Ther. 2011;11(9):1249-56. https://doi.org/10.1517/14712598.2011.602967 . 

    상세보기 crossref

  120. Stem Cell Res Ther. Y Qiu 8 1 136 2017 10.1186/s13287-017-0570-x Qiu Y, Li MY, Feng T, Feng R, Mao R, Chen BL, et al. Systematic review with meta-analysis: the efficacy and safety of stem cell therapy for Crohn’s disease. Stem Cell Res Ther. 2017;8(1):136. https://doi.org/10.1186/s13287-017-0570-x . 

    상세보기 crossref

  121. Aliment Pharmacol Ther PS Dulai 39 11 1266 2014 10.1111/apt.12753 Dulai PS, Gleeson MW, Taylor D, Holubar SD, Buckey JC, Siegel CA. Systematic review: the safety and efficacy of hyperbaric oxygen therapy for inflammatory bowel disease. Aliment Pharmacol Ther. 2014;39(11):1266-75. https://doi.org/10.1111/apt.12753 . 

    상세보기 crossref

  122. Aliment Pharmacol Ther V Vitton 21 12 1453 2005 10.1111/j.1365-2036.2005.02456.x Vitton V, Gasmi M, Barthet M, Desjeux A, Orsoni P, Grimaud JC. Long-term healing of Crohn’s anal fistulas with fibrin glue injection. Aliment Pharmacol Ther. 2005;21(12):1453-7. https://doi.org/10.1111/j.1365-2036.2005.02456.x . 

    상세보기 crossref

  123. 10.1053/j.gastro.2010.02.013 Grimaud JC, Munoz-Bongrand N, Siproudhis L, Abramowitz L, Senejoux A, Vitton V, et al. Fibrin glue is effective healing perianal fistulas in patients with Crohn’s disease. Gastroenterology. 2010;138(7):2275-81, 81 e1. https://doi.org/10.1053/j.gastro.2010.02.013 . 

    상세보기 crossref

  124. Colorectal Dis Y Nasseri 18 4 351 2016 10.1111/codi.13268 Nasseri Y, Cassella L, Berns M, Zaghiyan K, Cohen J. The anal fistula plug in Crohn’s disease patients with fistula-in-ano: a systematic review. Colorectal Dis. 2016;18(4):351-6. https://doi.org/10.1111/codi.13268 . 

    상세보기 crossref

  125. J Crohn’s Colitis. A Senejoux 10 2 141 2016 10.1093/ecco-jcc/jjv162 Senejoux A, Siproudhis L, Abramowitz L, Munoz-Bongrand N, Desseaux K, Bouguen G, et al. Fistula plug in fistulising ano-perineal Crohn’s disease: a randomised controlled trial. J Crohn’s Colitis. 2016;10(2):141-8. https://doi.org/10.1093/ecco-jcc/jjv162 . 

    상세보기 crossref

  126. Am J Surg J Moy 191 3 424 2006 10.1016/j.amjsurg.2005.10.050 Moy J, Bodzin J. Carbon dioxide laser ablation of perianal fistulas in patients with Crohn’s disease: experience with 27 patients. Am J Surg. 2006;191(3):424-7. https://doi.org/10.1016/j.amjsurg.2005.10.050 . 

    상세보기 crossref

  127. Tech Coloproctol P Giamundo 19 8 449 2015 10.1007/s10151-015-1282-9 Giamundo P, Esercizio L, Geraci M, Tibaldi L, Valente M. Fistula-tract Laser Closure (FiLaC): long-term results and new operative strategies. Tech Coloproctol. 2015;19(8):449-53. https://doi.org/10.1007/s10151-015-1282-9 . 

    상세보기 crossref

  128. Inflamm Bowel Dis C Ma 23 5 833 2017 10.1097/MIB.0000000000001074 Ma C, Fedorak RN, Kaplan GG, Dieleman LA, Devlin SM, Stern N, et al. Long-term maintenance of clinical, endoscopic, and radiographic response to ustekinumab in moderate-to-severe Crohn’s disease: real-world experience from a multicenter cohort study. Inflamm Bowel Dis. 2017;23(5):833-9. https://doi.org/10.1097/MIB.0000000000001074 . 

    상세보기 crossref

  129. Clin Gastroenterol Hepatol R Battat 2017 10.1016/j.cgh.2017.03.032 Battat R, Kopylov U, Bessissow T, Bitton A, Cohen A, Jain A, et al. Association among ustekinumab trough concentrations and clinical, biomarker, and endoscopic outcomes in patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2017. https://doi.org/10.1016/j.cgh.2017.03.032 . 

    상세보기 crossref

  130. Clin Gastroenterol Hepatol BE Sands 2 10 912 2004 10.1016/S1542-3565(04)00414-8 Sands BE, Blank MA, Patel K, van Deventer SJ, Study AI. Long-term treatment of rectovaginal fistulas in Crohn’s disease: response to infliximab in the ACCENT II Study. Clin Gastroenterol Hepatol. 2004;2(10):912-20. 

    상세보기 crossref

  131. Am J Gastroenterol. JF Colombel 104 5 1170 2009 10.1038/ajg.2009.59 Colombel JF, Sandborn WJ, Rutgeerts P, Kamm MA, Yu AP, Wu EQ, et al. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn’s disease: results from the CHARM trial. Am J Gastroenterol. 2009;104(5):1170-9. https://doi.org/10.1038/ajg.2009.59 . 

    상세보기 crossref
섹션별 컨텐츠 바로가기

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

AI-Helper 아이콘
AI-Helper
안녕하세요, AI-Helper입니다. 좌측 "선택된 텍스트"에서 텍스트를 선택하여 요약, 번역, 용어설명을 실행하세요.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.

선택된 텍스트

맨위로